Drugs / FALBIKITUG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03490669 | May 2018 → Sep 2019 | malignant pancreatic neoplasm, non-small cell lung carcinoma, ovarian cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05061550 | Apr 2022 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT04999969 | Dec 2021 → Oct 2024 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-28 | AstraZeneca | Results AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR astrazeneca.com ↗
AZD0171 (anti-LIF) combines productively with chemotherapy and anti-PD-L1 in mouse models of cancer |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-28 | AstraZeneca | AstraZeneca aims to transform the oncology treatment landscape with diverse early pipeline and novel combinations at AACR astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FALBIKITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315010 ↗ |
| Known as | AZD0171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04999969 ↗ |
| Known as | MSC-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03490669 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody (IgG1)” NCT03490669 ↗ |
| Route | Intravenous | “MSC-1 will be administered intravenously (IV)” NCT03490669 ↗ |
| Target | LIF | “binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF)” NCT03490669 ↗ |